Johns Hopkins University

Duke University

Other

Northwestern University

Sangeeta Ray

Martin Gilbert Pomper

Ronnie Charles Mease

Ying Chen

Xing Yang

Hassan Shallal

Samuel Ray Denmeade

Michael T McMahon

Michael R Zalutsky

Catherine Anne Foss

Xiaolei Song

Ganesan Vaidyanathan

Sachin S Chandran

Vivek Kumar

Thomas J Meade

Steven M Rowe

Il Minn

Sridhar Nimmagadda

Matthew W Rotz

Zaver Bhujwalla

Mohamad Allaf

Zhihang Chen

Cong Li

Michael Gorin

Marie-France Penet

Ishan Barman

Ming Li

Steven Rowe

Matthew Rotz

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

PSMA targeted fluorescent agents for image guided surgery

Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.

Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy

The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.

Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

PSMA-targeting compounds and uses thereof

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Triazole conjugated urea-based and thiourea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used to image cells and tumors that express PSMA. Methods of synthesizing radiofluorinated triazole conjugated urea-based and thiourea-based scaffolds also are disclosed.

Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof

Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.

Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof

PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.

68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents

Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof

Growing community of inventors

Ellicott City, MD, United States of America

Sangeeta Ray